NHP Urticaria Models

Urticaria (hives) is a common mast cell-driven disease characterized by wheal-and-flare reactions, erythema, and intense pruritus. It is classified as acute (≤6 weeks) or chronic (>6 weeks), and can be spontaneous or inducible by specific triggers (cold, pressure, allergens). HKeyBio offers two well-validated NHP urticaria models: (1) HDM induced urticaria model, established by epicutaneous or intradermal sensitization with house dust mite extract, recapitulating allergen-induced acute skin reactions; and (2) DNP-IgE & DNFB induced passive cutaneous anaphylaxis (PCA) model, a classical type I hypersensitivity model mediated by allergen-specific IgE and mast cell degranulation. Both models provide robust platforms for preclinical efficacy testing of novel anti-allergic and mast cell-stabilizing therapeutics.

Quantity:
Availability:





Inquire Add to Basket

Product Description

Key Features & Benefits

Clinically relevant – Two complementary models cover allergen-induced urticaria and passive IgE-mediated anaphylaxis, closely mimicking human disease.

Quantifiable endpoints – Clinical scores, wheal size, serum IgE, blood eosinophils, skin histopathology (HE, toluidine blue), mast cell degranulation.

Mechanism-driven – HDM model reflects environmental allergen sensitization; PCA model isolates IgE/mast cell axis.

Translational value – Ideal for testing anti-IgE biologics, mast cell stabilizers, H1-antihistamines, and anti-inflammatory agents.

IND-ready data packages – Studies can be conducted in accordance with GLP principles.

Technical Data & Validation

Representative data from our NHP Urticaria Model：

HDM Induced NHP Urticaria Model

•

HDM Induced NHP Urticaria Model

Applications

• Efficacy testing of anti-IgE biologics (omalizumab, ligelizumab), mast cell stabilizers (cromolyn), H1-antihistamines, and anti-inflammatory agents

• Target validation for IgE/FcεRI pathway and mast cell biology

• Biomarker discovery (IgE, eosinophils, mast cell mediators)

• Mechanism of action (MOA) studies for anti-allergic compounds

• IND-enabling safety pharmacology studies

Model Specifications

Parameter	HDM Induced Urticaria Model	DNP-IgE & DNFB Induced PCA Model
Species	Cynomolgus macaque (Macaca fascicularis)	Cynomolgus macaque (Macaca fascicularis)
Induction method	Repeated epicutaneous or intradermal HDM extract sensitization	Intradermal injection of DNP-IgE followed by DNFB challenge (topical or intradermal)
Study duration	4–6 weeks (sensitization + challenge)	1–2 weeks (passive sensitization + acute challenge)
Key endpoints	Clinical score (wheal/flare), serum IgE, blood eosinophils, skin H&E score, toluidine blue (mast cell degranulation), eosinophil infiltration	Wheal size, clinical feature, blood eosinophils (optional), mast cell degranulation
Data package	Raw data, analysis reports, clinical photographs, histology slides (HE, toluidine blue), bioinformatics (optional)

❓ Frequently Asked Questions

Q1: What urticaria models do you provide?

A1: We offer two non-human primate (NHP) models: HDM-induced urticaria model and DNP-IgE & DNFB-induced passive cutaneous anaphylaxis (PCA) model.

Q2: What are the modeling mechanisms?

A2: HDM acts as an allergen to trigger sensitization and challenge, causing typical wheal-and-flare skin reactions and mast cell degranulation. The PCA model induces type I hypersensitivity via IgE-mediated allergic responses.

Q3: What evaluation indicators are adopted?

A3: We observe clinical urticaria and PCA symptoms. We test eosinophils and mast cells, detect serum IgE, and conduct HE and toluidine blue staining for pathological analysis.

Q4: What are the modeling procedures and cycles?

A4: The HDM model includes sensitization and challenge phases, lasting 28 days in total. The PCA model completes IgE injection on Day 0 and DNFB stimulation on Day 1 for immediate reaction observation.

Q5: What are the advantages and applications?

A5: NHP models share high similarity with human skin and immune systems. They are ideal for efficacy evaluation and mechanism research of anti-urticaria and anti-allergic drugs.